PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Clinical trials for PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to fix chemo side effect that leaves cancer survivors at risk of bleeding
Disease control Recruiting nowThis study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…
Matched conditions: PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New combo aims to fix chemo side effect in cancer survivors
Disease control Recruiting nowThis study is for adults who have finished chemotherapy for gastrointestinal cancer and are in remission, but still have dangerously low platelet counts. Researchers want to see if adding a second drug (ATRA) to the standard platelet-boosting drug (romiplostim N01) works better t…
Matched conditions: PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 18, 2026 12:01 UTC